Sedana Medical shows significant health-economic benefits with AnaConDa

Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane sedation via AnaConDa versus conventional intravenous sedation with propofol or midazolam.

The analysis model has been developed to compare the costs and clinical outcome of sedated and ventilated intensive care patients. Clinical data is derived from a German retrospective study (Bellgardt et al., Eur J Anaesthesiology 2016, 33: 6-13), that compares in-hospital mortality and 365-day mortality for long-term ventilated ( > 96 hours) surgical intensive care unit patients sedated with either isoflurane via AnaConDa or sedated intravenously with propofol or midazolam. The costs included in the analysis are based on a published study of UK intensive care units in adult patients and current use of propofol and midazolam.

The conclusions of the analysis are:

• Sedation with isoflurane via AnaConDa significantly reduces mortality compared to propofol / midazolam.
• This mortality reduction is associated with a cost increase in the UK of £ 1,677 per patient.
• The total cost per death avoided is £ 7,943.

"The analysis is based on a large study showing that long-term sedation with isoflurane is not only a safe therapy, but also associated with an increased chance of survival, several months after treatment. The primary goal of intensive care is to save the patient's life. It is reassuring and positive that the cost is significantly less than what is required for a treatment to be considered cost-effective by the British Health Authority, the National Institute of Clinical Excellence (NICE)," says Peter Sackey, Chief Medical Officer of Sedana Medical.

"We have shown several times before that sedation with isoflurane via AnaConDa is a good therapy. However, getting concrete evidence that inhalation sedation is cost effective and what it costs to save a life is extremely important. It will facilitate future dialogue with payers in connection with the registration of IsoConDa (isoflurane)," says Christer Ahlberg, CEO of Sedana Medical.

In following link to ISPOR you will find the presentation:

https://tools.ispor.org/research_pdfs/60/pdffiles/PMD68.pdf 

Sedana Medical’s market in brief

Sedana Medical's market consists primarily of mechanically ventilated intensive care patients. The market for sedation of mechanically ventilated intensive care patients today consists of established drugs that are administered intravenously. The target group the company is focusing on are those patients who are ventilated for more than 24 hours, a target group that globally amounts to between two and four million patients per year. In total, the company consider this to be a market of SEK 10-20 billion per year, of which Europe accounts for about SEK 6 billion.

For additional information, please contact:

Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30,
E-mail: Christer.ahlberg@sedanamedical.com

Peter Sackey, CMO, Sedana Medical AB
Mobile: +46 70771 03 64
e-post: peter.sackey@sedanamedical.com 

Sedana Medical is listed on Nasdaq First North in Stockholm.
Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.

_________________________

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane)

Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.

Tags: